‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...

Related Keywords

United States , United Kingdom , China , California , South San Francisco , American , Danielle Haney , Adam Pryor , Levi Garraway , Loren Kalm , Bruno Eschli , Genentech , Global Product Development , Clinical Development Program , American Society Of Retina Specialists , Roche Group , Retina Specialists , Annual Meeting , Global Product , Disease Activity Criteria , Dosing Interval Assignment , Clinical Trial Patients With , Study Design , Underrepresented Patients With Diabetic Macular , Diabetic Retinopathy Symposium , Epiretinal Membrane Formation Over , Late Breaking , Reduces Macular Leakage , Patients With , Causes Rapid , Sustained Intraocular Suppression , Retinal Fluid Control With Faricimab , Rapidly Improves Fluid Parameters , Treatment Patterns , Diabetic Macular Edema Treated , Delivery System With Ranibizumab , Continuous Treatment , Additional Results From , Presentation Session , Uveitic Macular Edema , Novel Intravitreal , Preliminary Results From , Infectious Diseases , Clinical Development , Important Safety Information , Vabysmo Prescribing Information ,